Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
International Journal of Radiation Oncology*Biology*Physics · 2025-02 · 121 (2) · 341-351
DOI: 10.1016/j.ijrobp.2024.09.017 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-02. Verfasst von Nalee Kim und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymphatic Irradiation, Patient Reported Outcome Measures, Taxoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Korea Ministry of Health and Welfare.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: The role of regional node irradiation (RNI) with whole-breast irradiation (WBI) in patients with pN1 breast cancer receiving taxane-based adjuvant chemotherapy is not well defined. The KROG 1701 trial, a phase 3, multicenter, noninferiority study, aimed to compare the disease-free survival between WBI+RNI and WBI alone in this patient cohort. Comprehensive patient-reported outcomes (PROs) collected at multiple timepoints are reported. METHODS AND MATERIALS: The trial (NCT03269981) enrolled patients with pN1 breast cancer after breast-conserving surgery and taxane-based adjuvant chemotherapy, allocating them to receive either WBI+RNI or WBI only. PROs were assessed using European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30and breast cancer-specific module 23 modules at baseline, during radiation therapy, and at subsequent follow-up intervals of 3 to 6 months, and annually up to 4 years. RESULTS: From April 2017 to December 2021, 840 patients were enrolled; 777 received intervention as assigned, and 750 completed baseline PRO questionnaires (387 in WBI+RNI, 363 in WBI only). All PRO domains showed improvements over time (P < .001). During radiation therapy, the WBI+RNI group reported greater fatigue and nausea. Higher arm symptom scores were observed in the WBI+RNI group 3 months post-treatment (P = .030). No other significant PRO domain differences, including arm/breast symptoms, were observed between the 2 groups. CONCLUSIONS: In patients with pN1 breast cancer treated with taxane-based chemotherapy, adding RNI to WBI resulted in minor, temporary declines in specific PRO domains, but these differences were not clinically significant. This indicates that overall patient experience between WBI+RNI and WBI is comparable, supporting the safety and patient tolerability of both treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. Electronic address: wonro.park@samsung.com.
- Department of Radiation Oncology, Chonnam National University Medical School, Gwangju.
- Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu.
- Department of Radiation Oncology, Kyungpook National University School of Medicine, Daegu.
- Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul.
Förderung
- Korea Ministry of Health and Welfare
Zitieren
APA
Kim, N., Park, W., Kim, H., Cho, W. K., Ahn, S. J., Kim, M. Y., Park, S. H., Lee, I. J., Ha, I., Kim, J. H., Kim, T. H., Lee, K. C., Lee, H. S., Kim, T. G., Shin, K. H., Lee, J. H., Jung, J., Cho, O., Kim, Y. B., …, & Moon, S. (2025). Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01). International Journal of Radiation Oncology*Biology*Physics, 121(2), 341-351. https://doi.org/10.1016/j.ijrobp.2024.09.017
Vancouver
Kim N, Park W, Kim H, Cho WK, Ahn SJ, Kim MY, et al. Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01). International Journal of Radiation Oncology*Biology*Physics. 2025;121(2):341-351. doi:10.1016/j.ijrobp.2024.09.017
BibTeX
@article{Kim2025,
author = {Kim, Nalee and Park, Won and Kim, Haeyoung and Cho, Won Kyung and Ahn, Sung Ja and Kim, Mi Young and Park, Shin-Hyung and Lee, Ik Jae and Ha, Inbong and Kim, Jin Hee and Kim, Tae Hyun and Lee, Kyu Chan and Lee, Hyung-Sik and Kim, Tae Gyu and Shin, Kyung Hwan and Lee, Jong Hoon and Jung, Jinhong and Cho, Oyeon and Kim, Yong Bae and Kim, Eun Seog and Jo, In Young and Koo, Taeryool and Kim, Kyubo and Park, Hae Jin and Shin, Young-Joo and Ha, Boram and Kwon, Jeanny and Lee, Ju Hye and Moon, Sunrock},
title = {Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
volume = {121},
number = {2},
pages = {341--351},
doi = {10.1016/j.ijrobp.2024.09.017}
}
EUVIMED